{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:31:35Z","timestamp":1781177495632,"version":"3.54.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003968","name":"Iran National Science Foundation","doi-asserted-by":"publisher","award":["4003728"],"award-info":[{"award-number":["4003728"]}],"id":[{"id":"10.13039\/501100003968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006485","name":"National Institute for Genetic Engineering and Biotechnology","doi-asserted-by":"publisher","award":["010502-IV-816"],"award-info":[{"award-number":["010502-IV-816"]}],"id":[{"id":"10.13039\/501100006485","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropeptides"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.npep.2025.102522","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T12:03:49Z","timestamp":1746533029000},"page":"102522","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["PQK7: A novel peptide inhibitor targeting alpha-synuclein fibrillogenesis in Parkinson's disease"],"prefix":"10.1016","volume":"111","author":[{"given":"Maryam","family":"Motamedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Morshedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najaf Allahyari","family":"Fard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.npep.2025.102522_bb0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s13578-023-01152-x","article-title":"Clinical biomarkers for Lewy body diseases","volume":"13","author":"Abdelmoaty","year":"2023","journal-title":"Cell Biosci."},{"key":"10.1016\/j.npep.2025.102522_bb0010","article-title":"Molecular modeling in drug discovery","volume":"29","author":"Adelusi","year":"2022","journal-title":"Inf. Med. Unlocked"},{"issue":"4","key":"10.1016\/j.npep.2025.102522_bb0015","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jmb.2019.11.019","article-title":"Structural optimization of inhibitors of \u03b1-synuclein fibril growth: affinity to the fibril end as a crucial factor","volume":"432","author":"Afitska","year":"2020","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.npep.2025.102522_bb0020","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.46112","article-title":"An engineered monomer binding-protein for \u03b1-synuclein efficiently inhibits the proliferation of amyloid fibrils","volume":"8","author":"Agerschou","year":"2019","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.npep.2025.102522_bb0025","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-30209-y","article-title":"Investigation of the anti-TB potential of selected propolis constituents using a molecular docking approach","volume":"8","author":"Ali","year":"2018","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.npep.2025.102522_bb0030","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.32604\/biocell.2022.021224","article-title":"Pharmacotherapeutics and molecular docking studies of alpha-synuclein modulators as promising therapeutics for Parkinson\u2019s disease","volume":"46","author":"Ali","year":"2022","journal-title":"Biocell"},{"issue":"1","key":"10.1016\/j.npep.2025.102522_bb0035","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13024-023-00675-8","article-title":"Peptide-based approaches to directly target alpha-synuclein in Parkinson\u2019s disease","volume":"18","author":"Allen","year":"2023","journal-title":"Mol. Neurodegener."},{"issue":"2","key":"10.1016\/j.npep.2025.102522_bb0040","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1046\/j.1471-4159.2001.00408.x","article-title":"Identification of the region of non-A\u03b2 component (NAC) of Alzheimer\u2019s disease amyloid responsible for its aggregation and toxicity","volume":"78","author":"Bodles","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.npep.2025.102522_bb0045","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s12035-015-9148-8","article-title":"Pseudocatalytic antiaggregation activity of antibodies: immunoglobulins can influence \u03b1-synuclein aggregation at substoichiometric concentrations","volume":"53","author":"Breydo","year":"2016","journal-title":"Mol. Neurobiol."},{"issue":"1","key":"10.1016\/j.npep.2025.102522_bb0050","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1038\/s41467-021-21937-3","article-title":"The release of toxic oligomers from \u03b1-synuclein fibrils induces dysfunction in neuronal cells","volume":"12","author":"Cascella","year":"2021","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.npep.2025.102522_bb0055","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.3390\/ijms19103082","article-title":"Neuronal cell death mechanisms in major neurodegenerative diseases","volume":"19","author":"Chi","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.npep.2025.102522_bb0060","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.bbrc.2011.04.034","article-title":"The hexapeptide PGVTAV suppresses neurotoxicity of human \u03b1-synuclein aggregates","volume":"408","author":"Choi","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.npep.2025.102522_bb0065","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/cbdd.12055","article-title":"The future of peptide-based drugs","volume":"81","author":"Craik","year":"2013","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.npep.2025.102522_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-021-00799-8","article-title":"Regulated cell death: discovery, features and implications for neurodegenerative diseases","volume":"19","author":"Cui","year":"2021","journal-title":"Cell Commun. Signal"},{"issue":"11","key":"10.1016\/j.npep.2025.102522_bb0075","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","article-title":"Global, regional, and national burden of Parkinson\u2019s disease, 1990\u20132016: a systematic analysis for the global burden of disease study 2016","volume":"17","author":"Dorsey","year":"2018","journal-title":"The Lancet Neurol."},{"issue":"3","key":"10.1016\/j.npep.2025.102522_bb0080","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2174\/1573406411666141229163355","article-title":"Recent development of peptide drugs and advance on theory and methodology of peptide inhibitor design","volume":"11","author":"Du","year":"2015","journal-title":"Med. Chem."},{"key":"10.1016\/j.npep.2025.102522_bb0085","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1039\/D4SM01395F","article-title":"A study of alpha-synuclein and poly (N-isopropylacrylamide) complex formation through detailed atomistic simulations","volume":"21","author":"Ektirici","year":"2025","journal-title":"Soft Matter"},{"issue":"1","key":"10.1016\/j.npep.2025.102522_bb0090","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","article-title":"Peptide therapeutics: current status and future directions","volume":"20","author":"Fosgerau","year":"2015","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.npep.2025.102522_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2022.167714","article-title":"Functional and pathological effects of \u03b1-synuclein on synaptic SNARE complexes","volume":"435","author":"Gao","year":"2023","journal-title":"J. Mol. Biol."},{"issue":"23","key":"10.1016\/j.npep.2025.102522_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312827","article-title":"The MTT assay: utility, limitations, pitfalls, and interpretation in bulk and single-cell analysis","volume":"22","author":"Ghasemi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.npep.2025.102522_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.937133","article-title":"Neuronal cell death mechanisms in Alzheimer\u2019s disease: an insight","volume":"15","author":"Goel","year":"2022","journal-title":"Front. Mol. Neurosci."},{"issue":"9","key":"10.1016\/j.npep.2025.102522_bb0110","doi-asserted-by":"crossref","first-page":"896","DOI":"10.3390\/ph14090896","article-title":"In silico prediction of novel inhibitors of SARS-CoV-2 main protease through structure-based virtual screening and molecular dynamic simulation","volume":"14","author":"Halim","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.npep.2025.102522_bb0115","series-title":"Parkinson\u2019s Disease: Challenges, Progress, and Promise. National Institute of Neurological Disorders and Stroke","author":"Health UDo, Services H","year":"2021"},{"issue":"1","key":"10.1016\/j.npep.2025.102522_bb0120","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcad356","article-title":"Role of oxidative stress in neurodegenerative disorders: a review of reactive oxygen species and prevention by antioxidants","volume":"6","author":"Houldsworth","year":"2024","journal-title":"Brain Commun."},{"issue":"48","key":"10.1016\/j.npep.2025.102522_bb0125","doi-asserted-by":"crossref","first-page":"45320","DOI":"10.1074\/jbc.M103736200","article-title":"\u0391-Synuclein affects the MAPK pathway and accelerates cell death","volume":"276","author":"Iwata","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.npep.2025.102522_bb0130","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.biomag.2014.01.002","article-title":"In silico identification of potent inhibitors of alpha-synuclein aggregation and its in vivo evaluation using MPTP induced Parkinson mice model","volume":"4","author":"Jayaraj","year":"2014","journal-title":"Biomed. Aging Pathol."},{"issue":"3","key":"10.1016\/j.npep.2025.102522_bb0135","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0304-3940(02)00016-2","article-title":"Human \u03b1-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine","volume":"320","author":"Junn","year":"2002","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.npep.2025.102522_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00894-021-04968-x","article-title":"Destabilization of the Alzheimer\u2019s amyloid-\u03b2 peptide by a proline-rich \u03b2-sheet breaker peptide: a molecular dynamics simulation study","volume":"27","author":"Kanchi","year":"2021","journal-title":"J. Mol. Model."},{"issue":"4","key":"10.1016\/j.npep.2025.102522_bb0145","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.bbrc.2009.07.083","article-title":"\u03b2-Sheet-breaking peptides inhibit the fibrillation of human \u03b1-synuclein","volume":"387","author":"Kim","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"24","key":"10.1016\/j.npep.2025.102522_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232416096","article-title":"In silico study of the interactions of anle138b isomer, an inhibitor of amyloid aggregation, with partner proteins","volume":"23","author":"Kondratyev","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.npep.2025.102522_bb0155","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.bbrc.2008.01.140","article-title":"Sequence determinants regulating fibrillation of human \u03b1-synuclein","volume":"368","author":"Koo","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.npep.2025.102522_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105086","volume":"146","author":"Kumar","year":"2020","journal-title":"Neurobiol. Dis."},{"issue":"5","key":"10.1016\/j.npep.2025.102522_bb0165","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0197-4580(02)00196-3","article-title":"Cell cycle aberrations by \u03b1-synuclein over-expression and cyclin B immunoreactivity in Lewy bodies","volume":"24","author":"Lee","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.npep.2025.102522_bb0170","series-title":"Progress in Drug Research\/Fortschritte der Arzneimittelforschung\/Progr\u00e8s des recherches pharmaceutiques","first-page":"55","article-title":"The role of apoptosis in neurodegenerative diseases","author":"Lien","year":"1997"},{"issue":"3","key":"10.1016\/j.npep.2025.102522_bb0175","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.febslet.2013.12.015","article-title":"The N-terminus of \u03b1-synuclein is essential for both monomeric and oligomeric interactions with membranes","volume":"588","author":"Lorenzen","year":"2014","journal-title":"FEBS Lett."},{"issue":"2","key":"10.1016\/j.npep.2025.102522_bb0180","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.neulet.2011.01.026","article-title":"Over-expression of \u03b1-synuclein 98 triggers intracellular oxidative stress and enhances susceptibility to rotenone","volume":"491","author":"Ma","year":"2011","journal-title":"Neurosci. Lett."},{"issue":"25","key":"10.1016\/j.npep.2025.102522_bb0185","doi-asserted-by":"crossref","first-page":"7873","DOI":"10.1021\/ja075356q","article-title":"Design of an N-methylated peptide inhibitor of \u03b1-synuclein aggregation guided by solid-state NMR","volume":"130","author":"Madine","year":"2008","journal-title":"J. Am. Chem. Soc."},{"issue":"2","key":"10.1016\/j.npep.2025.102522_bb0190","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/35040009","article-title":"Apoptosis in neurodegenerative disorders","volume":"1","author":"Mattson","year":"2000","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.npep.2025.102522_bb0195","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3723762","article-title":"PD98059 protects brain against cells death resulting from ROS\/ERK activation in a cardiac arrest rat model","volume":"2016","author":"Nguyen Thi","year":"2016","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"12","key":"10.1016\/j.npep.2025.102522_bb0200","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.4103\/1673-5374.284993","article-title":"Small molecules to prevent the neurodegeneration caused by \u03b1-synuclein aggregation","volume":"15","author":"Pena-Diaz","year":"2020","journal-title":"Neural Regen. Res."},{"issue":"3","key":"10.1016\/j.npep.2025.102522_bb0205","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3934\/Neuroscience.2023017","article-title":"Depletion of dopamine in Parkinson\u2019s disease and relevant therapeutic options: a review of the literature","volume":"10","author":"Ramesh","year":"2023","journal-title":"AIMS neurosci."},{"issue":"7570","key":"10.1016\/j.npep.2025.102522_bb0210","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nature15368","article-title":"Structure of the toxic core of \u03b1-synuclein from invisible crystals","volume":"525","author":"Rodriguez","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.npep.2025.102522_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmgm.2021.108010","article-title":"Identification of new alpha-synuclein fibrillogenesis inhibitor using in silico structure-based virtual screening","volume":"108","author":"Sahihi","year":"2021","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.npep.2025.102522_bb0220","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.46775","article-title":"Inhibition of synucleinopathic seeding by rationally designed inhibitors","volume":"9","author":"Sangwan","year":"2020","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.npep.2025.102522_bb0225","article-title":"Mitogen-activated protein kinases and reactive oxygen species: how can ROS activate MAPK pathways?","volume":"2011","author":"Son","year":"2011","journal-title":"J. Signal Transduction"},{"key":"10.1016\/j.npep.2025.102522_bb0230","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.3389\/fonc.2020.01482","article-title":"SYPL1 inhibits apoptosis in pancreatic ductal adenocarcinoma via suppression of ROS-induced ERK activation","volume":"10","author":"Song","year":"2020","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.npep.2025.102522_bb0235","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nm0798-822","article-title":"\u03b2-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer\u2019s therapy","volume":"4","author":"Soto","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/j.npep.2025.102522_bb0240","doi-asserted-by":"crossref","DOI":"10.3389\/fddsv.2023.1314077","article-title":"Introduction to small molecule drug discovery and preclinical development","volume":"3","author":"Southey","year":"2023","journal-title":"Front. Drug Discovery"},{"issue":"9","key":"10.1016\/j.npep.2025.102522_bb0245","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.3390\/ijms19092486","article-title":"Investigation of \u03b1-synuclein amyloid fibrils using the fluorescent probe thioflavin T","volume":"19","author":"Sulatskaya","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"25","key":"10.1016\/j.npep.2025.102522_bb0250","doi-asserted-by":"crossref","first-page":"8637","DOI":"10.1073\/pnas.0712179105","article-title":"The fold of \u03b1-synuclein fibrils","volume":"105","author":"Vilar","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.npep.2025.102522_bb0255","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","article-title":"Therapeutic peptides: current applications and future directions","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"11","key":"10.1016\/j.npep.2025.102522_bb0260","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2300965120","article-title":"Chemical disaggregation of alpha-synuclein fibrils as a therapy for synucleinopathies","volume":"120","author":"Wu","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.npep.2025.102522_bb0265","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jmb.2009.03.053","article-title":"At low concentrations, 3, 4-dihydroxyphenylacetic acid (DOPAC) binds non-covalently to \u03b1-synuclein and prevents its fibrillation","volume":"388","author":"Zhou","year":"2009","journal-title":"J. Mol. Biol."}],"container-title":["Neuropeptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0143417925000228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0143417925000228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T07:58:12Z","timestamp":1762243092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0143417925000228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":53,"alternative-id":["S0143417925000228"],"URL":"https:\/\/doi.org\/10.1016\/j.npep.2025.102522","relation":{},"ISSN":["0143-4179"],"issn-type":[{"value":"0143-4179","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PQK7: A novel peptide inhibitor targeting alpha-synuclein fibrillogenesis in Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Neuropeptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.npep.2025.102522","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102522"}}